Company intelligence / Profile preview

Sequel Blu

Albuquerque, New Mexico, United Statesblu-ray.com ↗

Ownership: Private
Development stage: Other

Overview

Clinical trials have shown breakthrough results in lung and colorectal cancer detection using breath analysis. Technology has also demonstrated ability to diagnose COVID-19 including variant differentiation. Collaboration with University of Michigan on biomarker development for sepsis/ARDS.

Therapeutic areas: OncologyPulmonologyInfectious Diseases
Modalities: DeviceDiagnostic test (Micro Gas Chromatography Photoionization Detector)
Industry: Metabolite Diagnostics

Partnerships

University of Michigan College of Engineering & Weil InstituteInnovation Partnerships at U-M

Beyond the preview

Go deeper on Sequel Blu.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sequel Blu.

Explore the full profile